This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.Read Article
Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.Read Article
Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. During the pandemic era there was rapid adoption of telemedicine by rheumatologists; and a recent study of patient perspectives shows that most found telemedicine to be atRead Article
Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear. In fact, the investigatorsRead Article
Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors.
The retrospective study analyzed AEs obtained from WHO-VigiAccess and ascribed to tumor necrosisRead Article
A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.Read Article
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week withRead Article
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Findings A randomized, double-masked, placebo-controlled master protocol clinical trial found that treatment with abatacept ABA),Read Article
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particularRead Article
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.Read Article
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster. While our patients experience outsized morbidity from zoster, it has not been clear if herpes zoster vaccination is effective in them - but data at EULAR 2023 haveRead Article